Briarcliff Manor, NY, USA - Philips
Research announced today that it had received funding for phase one
of a planned four-year DARPA (Defense Advanced Research Projects
Agency) medical project to reduce the number of battlefield deaths
from internal bleeding. A consortium led by Philips Research will
develop a new medical technology that automatically detects and
stems the internal bleeding of wounded soldiers. The technology will
take the form of an ultrasound-based cuff device. Its application
could also be extended to prevent blood loss related civilian
deaths.
“Ninety percent of all combat deaths occur before a casualty reaches
a medical facility with definitive medical care so a tool that can
detect and reduce internal bleeding will help those trying to save
lives in the field” said Dr. Helen Routh, Principal Investigator and
General Manager of Philips Research. “In addition, these
technologies could also be used in civilian trauma situations,
giving substantial benefit to the public.”
Research into the proposed technology, “Autonomous Acoustic
Hemostasis”, will concentrate on the development of a high intensity
focused ultrasound (HIFU) technique for stemming internal bleeding
by encouraging coagulation. The technology will be so simple to use
that personnel with no medical training could successfully apply it.
Comprised of robust and lightweight cuffs applied to the arms and
legs of the wounded individual, the device will automatically detect
internal bleeding and use an ultrasound pulse to coagulate the blood
at the site of the trauma. This stems further blood-loss and allows
the casualty to be moved to a field hospital or Emergency Room.
In addition to helping the critically injured, the technology can
reduce the number of limbs lost and help identify those at risk of
progressive shock, which can quickly become life threatening.
The technology also promises to benefit the public by complementing
Philips Medical Systems’ solutions for the emergency medicine
market. The device could enable even minimally trained personnel to
potentially save lives, as is the case with the Philips HeartStart
defibrillator.
Philips Research is collaborating with researchers at the Applied
Physics Laboratory, University of Washington, Seattle; Philips
Applied Technologies, Houston, Pennsylvania and San Jose,
California; and Philips Medical Systems, Bothell, Washington and
Andover, Massachusetts.
Philips works with partner organizations to share insights. The
company’s strategy of Open Innovation, where exchange of knowledge
and expertise plays a vital role, is key to a successful innovation
process.
“We’ve assembled an outstanding multidisciplinary team of
researchers from the University of Washington, and Philips to work
towards the goal of improving outcomes from trauma with powerful new
tools that have real-life application,” said Dr. Lawrence Crum,
Principal Investigator for UW and Director of the Center for
Industrial and Medical Ultrasound at the Applied Physics Laboratory.
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a
global leader in healthcare, lighting and consumer lifestyle, delivering
people-centric, innovative products, services and solutions through the brand
promise of “sense and simplicity”. Headquartered in the Netherlands, Philips
employs approximately 134,200 employees in more than 60 countries worldwide.
With sales of EUR 27 billion in 2007, the company is a market leader in medical
diagnostic imaging and patient monitoring systems, energy efficient lighting
solutions, as well as lifestyle solutions for personal wellbeing. News from Philips is located at
www.philips.com/newscenter.
About University of Washington
For more than 25 years, the University of Washington has been among
the country's top five institutions in the dollar value of federal
research grants and contracts awarded to its faculty. Total grant
and contract activity for 2005 was nearly $1 billion. Serving 39,000
students, the UW's faculty includes five Nobel Laureates and the
winner of the 1990 National Book Award for Fiction.